Статті в журналах: "TTF triple"

1

Dranitsaris, George, Debu Tripathy, Nancy L. Beegle, Traci L. Kalberer, John David Cox, and Claudio Faria. "Real-world analysis of eribulin in metastatic breast cancer (MBC): An assessment of time to treatment failure (TTF) in a community oncology setting." Journal of Clinical Oncology 31, no. 26_suppl (September 10, 2013): 174. http://dx.doi.org/10.1200/jco.2013.31.26_suppl.174.

Повний текст джерела

Анотація:

174 Background: There have been important advances in the treatment of patients with MBC. However, certain patient subgroups such as whose who are triple negative remain a therapeutic challenge. Eribulin is the newest cytotoxic to gain regulatory approval for MBC in the Unites States. In this analysis, the safety and efficacy of eribulin in TNBC patients and those with prior anthracycline exposure were assessed in an early cohort treated in a U.S. community oncology setting. Methods: Ninety patients treated in eight community oncology clinics across the U.S. were identified. Patients were followed from the first cycle of eribulin until disease progression, discontinuation due to toxicity, or death. Data collection included baseline patient and disease characteristics, prior and subsequent anticancer therapy, use of supportive care drugs, number and type of dose limiting toxicity, delivered dose intensity, duration of eribulin therapy and time to treatment failure (TTF). Results: Eribulin was administered after a median of three prior lines of chemotherapy (range 0 to 15). The drug was delivered as a single agent in 79 of 90 patients (88%) at the clinically approved dosage of 1.4 mg/m2on days 1 and 8 of a 21 day cycle. Patients received a median of 4 cycles (1 to 16) for an overall mean duration of 2.9 months (0 to 14.2 months). Approximately 17 of 90 patients (18.9%) were identified as triple negative and 57 of 90 (63.3%) had received prior anthracycline treatment. The median TTF (inter quartile range) was 4 mon (2.3 to 5.6) in all patients. There were no significant differences in TTF by triple negative status (HR=0.1.22, p = 0.49) and prior exposure to anthracyclines (HR=0.78, p = 0.15). In all patients, the most common dose limiting toxicities were neutropenia (32%), anemia (31%), neuropathy (21%) and febrile neutropenia (8.9%). These events led to the premature discontinuation of eribulin in 8 of 90 patients (8.9%). Conclusions: TTF with eribulin was comparable regardless of triple negative status and prior exposure to anthracyclines. These findings are consistent with results from previous clinical studies and warrant further real-world analyses in a larger population.

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Dranitsaris, George, Stefan Glück, Claudio Faria, David Cox, and Hope S. Rugo. "A comparative effectiveness analysis of single-agent cytotoxics in triple-negative metastatic breast cancer patients." Journal of Clinical Oncology 32, no. 26_suppl (September 10, 2014): 157. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.157.

Повний текст джерела

Анотація:

157 Background: There has been considerable progress in treatments for MBC. However, the identification of optimal cytotoxic agents in patients with triple negative disease (negative for hormone receptors, ER/PR and HER-2) remains a therapeutic challenge. A comparative effectiveness analysis of four cytotoxic agents was conducted in patients with TN MBC. Methods: We retrospectively identified 225 patients treated with single agent eribulin (E=47), capecitabine (C=69), gemcitabine (G=56) or vinorelbine (V=53) in 19 community oncology clinics across the US. Data collection included baseline patient characteristics, performance status, duration of current therapy, growth factor use and all dose limiting toxicities. Time to treatment failure (TTF) was measured from the first cycle of chemotherapy until disease progression, discontinuation due to toxicity, or death. TTF was then estimated using the Kaplan-Meier method and Cox proportional hazard modeling adjusted for clustering on the practice site. To control for selection bias that is inherent in observational studies, a propensity score weighted TTF analysis was also conducted. Results: Patients were comparable with respect to age, performance status, duration of disease free survival, presence of comorbidities and hemoglobin level prior to the start of chemotherapy. However, the median lines of therapy for use of C, G, V and E were 2nd, 3rd, 3rd, and 4th, respectively. The median duration of treatment was approximately 2 months with C, G, and E compared to 1.6 months with V. Using eribulin as the reference and adjusting for line of therapy and associated prognostic factors, the propensity score weighted Cox regression analysis did not identify statistically significant differences in TTF: C vs. E: HR = 1.15 (0.75 to 1.76), G vs. E: HR = 0.62 (0.34 to 1.13), V vs. E: HR = 1.0 (0.60 to 1.37). Conclusions: In patients with TN-MBC treated in a community oncology setting, eribulin was utilized in later lines than other agents. However, eribulin demonstrated at least comparable drug activity even when used in more heavily pretreated patients. These findings warrant further analyses in a larger population with an evaluation of biologic heterogeneity.

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Maher, Mohamed, Shady H. E. Abdel Abdel Aleem, Ahmed M. Ibrahim, and Adel El-Shahat. "Novel Mathematical Design of Triple-Tuned Filters for Harmonics Distortion Mitigation." Energies 16, no. 1 (December 21, 2022): 39. http://dx.doi.org/10.3390/en16010039.

Повний текст джерела

Анотація:

The design of AC filters must meet the criteria of harmonic distortion mitigation and reactive power support in various operating modes. The stringent reactive power-sharing requirements currently lead to sophisticated filter schemes with high component ratings. In this regard, triple-tuned filters (TTFs) have good potential in harmonic mitigation of a broad range of harmonics. In the literature, the TTF design has been presented using a parametric method, assuming that the TTF is equivalent to a three-arm single-tuned filter (TASTF). However, no direct methods of designing it or finding its optimal parameters have been provided. This paper presents novel mathematical designs of TTFs. Three different design methods are considered—the direct triple-tuned filter (DTTF) design method, as a TASTF, and a method based on the equivalence between the two design methods called the equivalence hypothesis method to design the triple-tuned filter (EHF). The parameters of the three proposed design methods are optimized based on the minimization of a proposed multi-objective function using a recent metaheuristic algorithm called artificial rabbits optimization (ARO) to mitigate harmonics, improve power quality, and minimize power losses in an exemplary system presented in IEEE STD-519. Further, the system’s performance has been compared to the system optimized by the ant lion optimizer (ALO) and whale optimization algorithm (WOA) to validate the effectiveness of the proposed design. Simulation results emphasized harmonics mitigation in the system, the system losses reduction, and power quality improvement with lower reactive power filter ratings than conventional single and double-tuned filters.

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Ahn, Sejung, Yukyung Kim, Seungjae Beak, Shohei Ishimoto, Hideo Enozawa, Eigo Isomura, Masashi Hasegawa, Masahiko Iyoda, and Yungwoo Park. "Synthesis and electrical conductivity of perchlorate-doped TTF–diamide nanofibers with double and triple helix structures." Journal of Materials Chemistry 20, no. 48 (2010): 10817. http://dx.doi.org/10.1039/c0jm02628j.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Schwingshackl, Andreas, Benjamin Lopez, Bin Teng, Charlean Luellen, Florian Lesage, John Belperio, Riccardo Olcese, and Christopher M. Waters. "Hyperoxia treatment of TREK-1/TREK-2/TRAAK-deficient mice is associated with a reduction in surfactant proteins." American Journal of Physiology-Lung Cellular and Molecular Physiology 313, no. 6 (December 1, 2017): L1030—L1046. http://dx.doi.org/10.1152/ajplung.00121.2017.

Повний текст джерела

Анотація:

We previously proposed a role for the two-pore domain potassium (K2P) channel TREK-1 in hyperoxia (HO)-induced lung injury. To determine whether redundancy among the three TREK isoforms (TREK-1, TREK-2, and TRAAK) could protect from HO-induced injury, we now examined the effect of deletion of all three TREK isoforms in a clinically relevant scenario of prolonged HO exposure and mechanical ventilation (MV). We exposed WT and TREK-1/TREK-2/TRAAK-deficient [triple knockout (KO)] mice to either room air, 72-h HO, MV [high and low tidal volume (TV)], or a combination of HO + MV and measured quasistatic lung compliance, bronchoalveolar lavage (BAL) protein concentration, histologic lung injury scores (LIS), cellular apoptosis, and cytokine levels. We determined surfactant gene and protein expression and attempted to prevent HO-induced lung injury by prophylactically administering an exogenous surfactant (Curosurf). HO treatment increased lung injury in triple KO but not WT mice, including an elevated LIS, BAL protein concentration, and markers of apoptosis, decreased lung compliance, and a more proinflammatory cytokine phenotype. MV alone had no effect on lung injury markers. Exposure to HO + MV (low TV) further decreased lung compliance in triple KO but not WT mice, and HO + MV (high TV) was lethal for triple KO mice. In triple KO mice, the HO-induced lung injury was associated with decreased surfactant protein (SP) A and SPC but not SPB and SPD expression. However, these changes could not be explained by alterations in the transcription factors nuclear factor-1 (NF-1), NKX2.1/thyroid transcription factor-1 (TTF-1) or c-jun, or lamellar body levels. Prophylactic Curosurf administration did not improve lung injury scores or compliance in triple KO mice.

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Peng, Yan, Yasmeen M. Butt, Beiyun Chen, Xinmin Zhang, and Ping Tang. "Update on Immunohistochemical Analysis in Breast Lesions." Archives of Pathology & Laboratory Medicine 141, no. 8 (June 5, 2017): 1033–51. http://dx.doi.org/10.5858/arpa.2016-0482-ra.

Повний текст джерела

Анотація:

Context.— The utility of immunohistochemistry (IHC) in breast lesions needs to be updated with exceptions among these lesions. Biomarker studies with IHC in triple-negative breast carcinoma may help develop targeted therapies for this aggressive breast cancer. The distinction of metastatic lung adenocarcinoma to the breast and invasive breast carcinoma has significant prognostic and therapeutic implications. The determination can be challenging because both primary tumors can express estrogen receptor and/or HER2 by IHC, creating a diagnostic dilemma. Objectives.— To provide a practical update on the use of IHC markers in differential diagnoses in breast lesions, including benign, atypical, precancerous, and malignant tumors; to highlight recently published research findings on novel IHC markers in triple-negative breast carcinoma cases; and to reinforce the importance of IHC use as an ancillary tool in distinguishing metastatic lung adenocarcinoma to the breast from primary breast carcinoma using real case examples. Data Sources.— PubMed (US National Library of Medicine, Bethesda, Maryland) literature review and authors' research data and personal experiences were used in this review. Conclusions.— Immunohistochemistry has an important role in making differential diagnoses in breast lesions in morphologically equivocal settings; recognizing IHC expression status in the exceptions among these lesions will aid in the correct diagnosis of challenging breast cases. Studies suggest that androgen receptor, p16, p53, GATA3, and PELP1 may have potential diagnostic, prognostic, and predictive value in triple-negative breast carcinoma cases; these findings may provide insight and a greater understanding of the tumor biology in triple-negative breast carcinomas. In distinguishing metastatic estrogen receptor–positive or HER2+ lung adenocarcinoma to the breast from primary breast carcinoma, napsin A, TTF-1, and GATA3 comprise a useful IHC panel.

Стилі APA, Harvard, Vancouver, ISO та ін.

7

El-Maqsoud, Nehad M. R. Abd, Ehab Rifat Tawfiek, Ayman Abdelmeged, Mohamed Fathy Abdel Rahman, and Alaa A. E. Moustafa. "The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas." Tumor Biology 37, no. 3 (October 1, 2015): 3123–34. http://dx.doi.org/10.1007/s13277-015-3964-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Spiegel, Jay, Caroline Jane McNamara, Andrea Arruda, Tony Panzarella, James A. Kennedy, Tracy L. Stockley, Mahadeo Sukhai, et al. "Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy." Blood 128, no. 22 (December 2, 2016): 4263. http://dx.doi.org/10.1182/blood.v128.22.4263.4263.

Повний текст джерела

Анотація:

Abstract Introduction: The advent of next generation sequencing (NGS) has brought intense interest to the complex genetic landscape of myeloproliferative neoplasms (MPN). However, data regarding clinical outcomes in the context of novel MPN therapies such as JAK inhibitors are scarce. Limited data indicate that high molecular risk signature (HMR, presence of at least one mutation in ASXL1, EZH2, IDH1/2, SRSF2) or multiple mutations may be associated with decreased spleen response and a shorter time to discontinuation of Ruxolitinib in myelofibrosis (Patel et al, Blood 2015). Methods: All myelofibrosis patients seen in the MPN program at Princess Margaret Hospital between November 2009 and May 2016 and treated with JAK1/2 inhibitor therapy were identified. NGS molecular profiling of 54 genes (39 hotspot region; 15 complete coding region coverage) was performed on peripheral blood or bone marrow samples using the TruSight Myeloid Sequencing Panel. Reporting was restricted to well-covered, exonic nonsynonymous, intronic splice site, and known pathogenic synonymous variants. Variants with global mean allele frequency >1% were identified using multiple population databases (1000 genomes, ESP, ExAC) and excluded. The primary endpoint was time from start of JAK1/2 inhibitor therapy to treatment failure (TTF) defined as treatment discontinuation, progression to accelerated phase or leukemic transformation, spleen progression or death. Secondary endpoints included best spleen, anemia and IWG response achieved by 48 weeks of treatment and overall survival. Response was assessed according to the 2013 revised IWG-MRT criteria. Transfusion dependency was assessed as any transfusion in 12 weeks prior to treatment or being identified as transfusion dependent in medical history. Results: Of 159 patients treated with JAK1/2 inhibitors at our institution, 102 met the inclusion criteria (see Table 1). Patients were excluded if; no sample was available for analysis (19), short use of JAK inhibitor prior to transplant (9), active clinical trial (5), in accelerated phase/acute leukemia (4) and others (20). First JAK inhibitor used was ruxolitinib in 77 patients and momelotinib in 25. At least one mutation was identified in every patient. Twenty (20%) patients had one mutation, 32 (31%) had 2 mutations and 50 (49%) patients had ≥ 3 mutations. Eighty (82%) patients had the JAK2V617F mutation, 15 (15%) had mutations in CALR, 4 (4%) had MPL mutations and one patient was triple negative. One patient had mutations in both CALR and JAK2 while another had mutations in MPL and CALR. Forty-eight (47%) patients had mutations consistent with HMR profile. Mutation profile is summarized in Table 2. With median follow-up of 2.5 years, 51 (50%) patients experienced treatment failure. On univariate analysis, TTF was associated with DIPSS, pre-treatment transfusion status and Hb <100 prior to initiating JAK inhibitor therapy. However, TTF was not associated with specific driver mutations, the number of mutations or HMR profile. Exploratory analysis of genes mutated in ≥5% of the population showed EZH2 (p=0.004) and CBL (p=0.005) mutated patients had shorter TTF. Multi-variable analysis employing anemia <100 and DIPSS with either of the number of mutations or HMR profile did not show any association with TTF. There was a trend towards TTF in patients with Hb<100 (HR 2.21, 95%CI: 0.99-4.95, p=0.05). Of 102 patients, 91 were evaluable for spleen response with 43 (47%) achieving a spleen response by 48 weeks of treatment. Twelve (23%) of the 53 patients evaluated met criteria for anemia response. Neither spleen nor anemia response was associated with the use of a particular JAK inhibitor. Of the 95 patients with at least 48-week follow-up, best response while on treatment was clinical improvement and spleen response in 29 (31%) and 19 (20%) patients respectively. Conclusions: In this study of myelofibrosis patients treated with JAK inhibitors, EZH2 and CBL mutated patients had shorter TTF. We did not find any association between TTF and number of mutations or other high risk mutations such as ASXL1/SRSF2. Anemia was the only significant independent predictor of shorter TTF. Our findings highlight the need for multicenter collaborative studies on a large number of patients and cautious use of mutation profiling results in routine clinical decision making with current treatment approaches. Spiegel and McNamara are co-primary authors. Disclosures Panzarella: Cellgene: Consultancy. Schimmer:Novartis: Honoraria. Schuh:Amgen: Membership on an entity's Board of Directors or advisory committees. Yee:Novartis Canada: Membership on an entity's Board of Directors or advisory committees, Research Funding. Kamel-Reid:BMS: Research Funding. Gupta:Novartis: Consultancy, Honoraria, Research Funding; Incyte Corporation: Consultancy, Research Funding.

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Eisen, Tim, Yaroslav Shparyk, Robert Jones, Nicholas James MacLeod, Graham Temple, Helen Finnigan, Rolf Kaiser, Matus Studeny, Arsene Bienvenu Loembe, and Igor Bondarenko. "Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 4506. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4506.

Повний текст джерела

Анотація:

4506 Background: Sunitinib (S) is established as a standard first-line therapy for patients (pts) with advanced RCC. However, treatment can be limited by the occurrence of drug-related adverse events (AEs). This Phase II study assessed the efficacy and safety of nintedanib (N) – a potent, triple angiokinase inhibitor of VEGFR-1–3, PDGFR-α/β, and FGFR-1–3, as well as RET and Flt3 – vs S in previously untreated pts with RCC. Methods: Ninety-nine eligible pts (96 of whom were treated) with advanced, unresectable/recurrent clear cell RCC, an ECOG performance status of 0–1, and no prior systemic therapy were randomized 2:1 to receive N 200 mg twice daily (n=64; given in 4-week cycles) or S 50 mg once daily (n=32; 4 weeks on, 2 weeks off schedule). Treatment continued until disease progression or unacceptable drug-related AEs. Primary endpoints were progression-free survival at 9 months (PFS-9) and, in N-treated pts only, QTc interval change (baseline to day 15). Secondary endpoints included PFS, objective response rate (ORR; RECIST 1.1), overall survival (OS), time to progression (TTP), time to treatment failure (TTF), and AEs. Results: Baseline characteristics were balanced between the arms. PFS-9 was not statistically significantly different between N- and S-treated pts (43 vs 45%; p=0.85). There were also no statistically significant differences between N and S with regard to PFS (median: 8.44 vs 8.38 mo; hazard ratio: 1.16; 95% CI: 0.71–1.89; p=0.56), confirmed ORR (18.8 vs 31.3%; p=0.19), OS (median: 20.37 vs 21.22 mo; p=0.63), TTP (median: 8.48 vs 8.54 mo; p=0.52), and TTF (median: 8.41 vs 8.36 mo; p=0.46). Grade ≥3 AEs occurred in 47% of N-treated pts and 56% of S-treated pts. Common AEs (all grades; N vs S) included diarrhea (61 vs 50%), nausea (38 vs 34%), fatigue (both 25%), and vomiting (16 vs 22%). Dermatologic AEs (8 vs 47%) were less frequent with N than S. There was no increase from baseline in QTc >60 ms on days 1 or 15 in N-treated pts, and there was no relationship between N exposure and QT interval change. Conclusions: N demonstrated similar efficacy to S and had a manageable safety profile, including a lower incidence of dermatologic AEs vs S. In addition, N was not associated with QT prolongation. Clinical trial information: NCT01024920.

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Sharma, Rajni, Grzegorz Gurda, Susan Geddes, Edward Gabrielson, Frederic Askin, and Qing Kay Li. "Validation of the Novel Triple Marker (Combination of TTF, Napsin-A and p40) in the Subclassification of Non-Small Cell Lung Carcinomas (NSCLC) Using Fine Needle Aspiration (FNA) Cytological Materials." Journal of the American Society of Cytopathology 3, no. 5 (September 2014): S83. http://dx.doi.org/10.1016/j.jasc.2014.09.195.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Daub, Nicolas. "A Critical Approach to Multi-Electron Materials for High Energy Density Non-Aqueous Redox Flow Batteries." ECS Meeting Abstracts MA2022-01, no. 48 (July 7, 2022): 2030. http://dx.doi.org/10.1149/ma2022-01482030mtgabs.

Повний текст джерела

Анотація:

Redox flow batteries (RFBs) are very promising storage systems in the transition towards renewable energy sources. They can be broadly classified in aqueous and non-aqueous systems. Last-named operate with organic solvents, which allow for a much broader potential window (up to three times higher) compared to water. Combination of organic solvents with organic redox active materials could pave the way for all carbon-based RFBs with superior energy densities compared to aqueous systems. In this contribution, newly developed organic electrolytes will be presented, focusing on their performance as RFB materials in acetonitrile with quaternary ammonium electrolyte salts. To push the limits of energy density, we investigated multi-electron reduction and oxidation reactions on a single molecule. As catholyte, tetrathiafulvalene (TTF) as a core structure was used. The unsubstituted TTF exhibits two reversible oxidation events (-0.04 and +0.34 V vs Fc/Fc+) but a poor solubility in acetonitrile. To optimize this and to achieve a higher oxidation potential a series of molecules with different side chains was synthesized. The resulting solubilities led to volumetric capacities of up to 71 Ah/L for the newly designed compounds. Electrochemical cycling stability was evaluated in bulk electrolysis, UV-Vis-NIR and flow cycling experiments. Current state-of-the-art anolytes based on N-methylphthalimide compounds exhibit one reversible reduction pair at a desirable low reduction potential (-1.87 V vs Fc/Fc+) and good cycling stability in bulk electrolysis experiments.[1] Expanding on this structure, new derivatives with one or two additional functional imide groups per phthalimide core were synthesized. Consequently, molecules with a single (-1.87 V vs Fc/Fc+), double (-1.26 and -1.88 V vs Fc/Fc+) and triple reduction event (-1.02, -1.65 and -2.37 V vs Fc/Fc+) can be obtained. To optimize their solubility in acetonitrile, a series of molecules with different side chains was synthesized for each of the three core structures. Determination of the solubility led to volumetric capacities of up to 66 Ah/L for the newly developed compounds. Additionally, we tested the electrochemical cycling stability in bulk electrolysis, UV-Vis-NIR, coin cell and flow cycling experiments. In the final flow battery, a high energy density of 24 Wh/L was achieved (at 1 M of transferred electrons).[2] All of this led to a critical comparison between the different molecular designs, cumulating in design rules that will influence future designs of the organic redox active compounds for organic RFBs. [1] Wei, X.; Duan, W.; Huang, J.; Zhang, L.; Li, B.; Reed, D.; Xu, W.; Sprenkle, V.; Wang, W. A High-Current, Stable Nonaqueous Organic Redox Flow Battery. ACS Energy Lett. 2016, 1, 705−711 [2] Daub, N.; Janssen, R. A. J.; Hendriks, K. H. Imide-Based Multielectron Anolytes as High-Performance Materials in Nonaqueous Redox Flow Batteries. ACS Appl. Energy Mater. 2021, 4, 9, 9248–9257

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Angeleri Hügel, Lidia, and Silvana Bazzoni. "TTF Triples in Functor Categories." Applied Categorical Structures 18, no. 6 (March 12, 2009): 585–613. http://dx.doi.org/10.1007/s10485-009-9188-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Netterwald, James. "TNF-blocker triple approval." Nature Biotechnology 27, no. 6 (June 2009): 495. http://dx.doi.org/10.1038/nbt0609-495.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Hegner, Björn, Theres Schaub та Duska Dragun. "Editorial: Triple-agent TGF-β". Journal of Leukocyte Biology 93, № 4 (квітень 2013): 459–62. http://dx.doi.org/10.1189/jlb.1212652.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Jackson, Raef, Carmen Francis, Karim Awad, and Semiu E. Folaranmi. "Triple Atresia, Triple Threat? An Unusual Constellation of Primary Surgical Abnormalities." Pediatric Reports 13, no. 2 (April 12, 2021): 189–96. http://dx.doi.org/10.3390/pediatric13020026.

Повний текст джерела

Анотація:

We present a case series of two patients with tracheo-oesophageal fistula with oesophageal atresia (TOF/OA), duodenal atresia (DA) and ano-rectal malformation (ARM). This constellation of abnormalities, dubbed triple atresia (TA), is a rare combination with few described cases in the literature. Here we describe our management of these cases, as well as the results of our literature review. Both of our cases had staged surgical procedures and were initially managed with thoracotomy for repair of TOF/OA on day two of life. They subsequently underwent laparotomy for management of their abdominal pathology at day five and seven of life. Both have survived the neonatal period and are awaiting definitive surgery for ARM. Literature review yielded seven cases of TA involving a TOF, DA, and ARM. Four patients underwent staged repair, while three patients underwent repair of TOF/OA, DA and colostomy for ARM at the same time. Of these three patients, two died, representing 22% of the overall cohort. Triple atresia remains a rare subset of patients suspected to have VACTERL association, however mortality may be significantly higher. Our data would suggest a staged approach to be optimal for long term survival.

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Deng, Kewei, and Liqian Luo. "Analysis of the Application Value of Different Esophagography Techniques in the Diagnosis of H-Type Tracheoesophageal Fistula in Neonates." Evidence-Based Complementary and Alternative Medicine 2022 (July 13, 2022): 1–5. http://dx.doi.org/10.1155/2022/7264343.

Повний текст джерела

Анотація:

Objective. The study aimed to analyse the detection rates of the triple-lumen double-balloon catheter technique and conventional esophagography in diagnosing H-type tracheoesophageal fistula (H-TEF) in neonates. Methods. The data of 8 neonates diagnosed with H-TEF by surgery in the researchers’ hospital between January 2015 and January 2022 were collected. We compared the detection (true positive) rates of H-TEF by the triple-lumen double-balloon catheter technique, conventional esophagography, and multidetector row spiral CT. Results. Before surgery, conventional esophagography was applied in all 8 cases, of which the H-TEF diagnosis was confirmed in 5 cases and TEF was suspected in 3 cases. The triple-lumen double-balloon catheter technique was employed in 5 cases, of which 4 were confirmed with H-TEF and 1 was suspected with TEF. Multidetector row spiral CT was performed in 4 cases, and 1 case was confirmed with H-TEF, while no fistula was observed in the other 3 cases. The triple-lumen double-balloon catheter technique yielded a 100% detection rate, while conventional esophagography revealed a 62.5% rate and multidetector row spiral CT showed a 25% rate. By comparative analysis, the true positive rates (TPRs) of the triple-lumen double-balloon catheter technique and conventional esophagography were not significantly different ( P = 0.118 ). No significant differences were recorded in TPRs between conventional esophagography and multidetector row spiral CT ( P = 0.221 ). However, the triple-lumen double-balloon catheter technique had a significantly higher TPR than multidetector row spiral CT ( P = 0.118 ). Conclusion. To diagnose congenital H-TEF in neonates, conventional esophagography is a highly valuable yet inconsistently reliable method and the diagnostic value of CT is relatively limited. The triple-lumen double-balloon catheter technique boasts a significantly valuable application for H-TEF diagnosis. Being simple, economical, and effective, it barely requires state-of-the-art facilities, and no complications have occurred during its clinical practice. These advantages justify a possible wider application of the triple-lumen double-balloon catheter technique in clinical practice.

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Tu, Cheng, Ming-hong Yang, Zi-qiang Zhang, Xiu-mei Lv, Lei Li, and Xiao-Sheng Zhang. "Highly Sensitive Temperature Sensor Based on Coupled-Beam AlN-on-Si MEMS Resonators Operating in Out-of-Plane Flexural Vibration Modes." Research 2022 (August 21, 2022): 1–9. http://dx.doi.org/10.34133/2022/9865926.

Повний текст джерела

Анотація:

This paper reports a type of highly sensitive temperature sensor utilizing AlN-on-Si resonators with coupled-beam structures of double- and triple-ended-tuning-fork (D/TETF). For both resonators, the out-of-plane flexural mode is adopted as it favors the effect of thermal mismatch between the composite layers inherent to the AlN-on-Si structure and thus helps attain a large temperature coefficient of resonant frequency (TCF). The analytical model to calculate TCF values of D/TETF AlN-on-Si resonators is provided, which agrees well with the finite-element simulation and experimental results. The resonant temperature sensor is built by closing the loop of the AlN-on-Si resonator, a transimpedance amplifier, a low-pass filter, and a phase shifter to form an oscillator, the output frequency of which shifts proportionally to the ambient temperature. The measured sensitivities of the temperature sensors using D/TETF resonators are better than -1000 ppm/°C in the temperature range of 25°C~60°C, showing great potential to fulfill the on-chip temperature compensation scheme for cofabricated sensors.

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Kim, Sung-Bae, Qingyuan Zhang, Tao Sun, Jae Hong Seo, Keun Seok Lee, Tae-Yong Kim, Zhongsheng Tong, et al. "[OPTIMAL 3] A phase III trial to evaluate the efficacy and safety of DHP107 (Liporaxel, oral paclitaxel) compared to Taxol (IV paclitaxel) as first line therapy in patients with recurrent or metastatic HER2 negative breast cancer (BC) (NCT03315364)." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): TPS1106. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps1106.

Повний текст джерела

Анотація:

TPS1106 Background: Paclitaxel is a microtubule-stabilizing drug used for various cancers including breast cancer (BC) and gastric cancer (GC). DHP107 is an oral paclitaxel solution formulated with non-toxic excipients using DH-LASED technology, which doesn’t require pre-treatment. DHP107 demonstrated comparable efficacy and safety to IV paclitaxel for patients with advanced GC (Ann Oncol 2018), and was market approved as the first oral paclitaxel in 2016 for GC in Korea. In previous OPTIMAL phase II study, the primary endpoint objective response rate (ORR) was 54.5% in HER2 negative metastatic BC (MBC) patients and 44.4% in triple negative BC (TNBC) patients. Disease control rate (DCR) was 90.9% by the investigators’ assessment. Toxicity was manageable (2019 ESMO). OPTIMAL phase III is being conducted in Korea, China and Eastern Europe based on this result and another phase II study (OPERA) is being performed in USA. Methods: OPTIMAL 3 study is a multinational, multi-center, randomized and open-label trial enrolling HER2 negative (HR+/HER2- or TNBC) recurrent or metastatic BC patients. Patients are randomized to either study (DHP107) or control group (IV paclitaxel) in a 1:1 ratio and stratified by disease free interval (DFI≤48 weeks vs >48 weeks), visceral metastasis status (visceral vs non-visceral) and country. Patients are administrated with DHP107 (200mg/m2 p.o. bid) or IV paclitaxel (80mg/m2 infused) on D1, 8, 15, q4wks. Tumor assessments are performed on every 8 weeks (±7 days) from C1D1 until disease progression (RECIST V1.1). Key inclusion & exclusion criteria are hormone receptor (ER/PR) positive or negative, HER2 negative, ECOG performance status ≤1 and no prior chemotherapy in recurrent or metastatic disease. The primary endpoint is progression free survival (PFS). Secondary endpoints include ORR, overall survival (OS), time to treatment failure (TTF), DCR, quality of life (QoL) and safety. Total target number of patients is 476 with an estimated 10% drop-out rate. The test is based on non-inferiority hypothesis (HR=1.33) with 80% power. The primary endpoint will be analyzed using a one-sided test at a 2.5% significance level, and other endpoints will be analyzed using a two-sided test at a 5% significance level, with 95% confidence interval. The first subject was enrolled in Jan 2019 and recruitment is ongoing and is expected to be completed in Dec 2020. Final results of this study will be announced by the end of 2022. Clinical trial information: NCT03315364 .

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Liao, Hsien-Tzung, and Chang-Youh Tsai. "Cytokines and regulatory T cells in ankylosing spondylitis." Bone & Joint Research 12, no. 2 (February 6, 2023): 133–37. http://dx.doi.org/10.1302/2046-3758.122.bjr-2022-0195.r1.

Повний текст джерела

Анотація:

AimsTo investigate the correlations among cytokines and regulatory T cells (T-regs) in ankylosing spondylitis (AS) patients, and their changes after anti-tumour necrosis factor-α (TNF-α) treatment.MethodsWe included 72 AS patients with detailed medical records, disease activity score (Bath Ankylosing Spondylitis Disease Activity Index), functional index (Bath Ankylosing Spondylitis Functional Index), and laboratory data (interleukin (IL)-2, IL-4, IL-10, TNF-α, interferon (IFN)-γ, transforming growth factor (TGF)-β, ESR, and CRP). Their peripheral blood mononuclear cells (PBMCs) were marked with anti-CD4, anti-CD25, and anti-FoxP3 antibodies, and triple positive T cells were gated by flow cytometry as T-regs. Their correlations were calculated and the changes after anti-TNF-α therapy were compared.ResultsThe frequency of T-regs in PBMCs was positively correlated to ESR and CRP in AS (r = 0.35 and 0.43; p = 0.032 and 0.027, respectively), and there was also a significant correlation between serum level of TNF-α and CRP (p = 0.041). The frequency of T-regs in PBMCs positively correlated to serum levels of TNF-α, IL-10, and TGF-β, while IL-2, IL-4, and IFN-γ showed opposite results. After anti-TNF-α treatment, there were significantly lower serum levels of TNF-α, IL-10, TGF-β, and frequency of T-regs in PBMCs among these AS patients (p = 0.026, 0.032, 0.029, and 0.037, respectively).ConclusionIn AS patients, proinflammatory cytokine may give positive feedback to induce more T-reg production and anti-inflammatory cytokine secretion to suppress this inflammatory status, and they can be reversed by anti-TNF-α therapy. However, the detailed interactions among T-regs and complex cytokine networks in autoinflammatory diseases still need more studies and further functional assay.Cite this article: Bone Joint Res 2023;12(2):133–137.

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Azemar, Fabrice, Olinda Gimello, Julien Pinaud, Jean-Jacques Robin, and Sophie Monge. "Insight into the Alcohol-Free Ring-Opening Polymerization of TMC Catalyzed by TBD." Polymers 13, no. 10 (May 14, 2021): 1589. http://dx.doi.org/10.3390/polym13101589.

Повний текст джерела

Анотація:

We report herein a study on the alcohol-free, ring-opening polymerization of trimethylene carbonate (TMC) in THF, catalyzed by 1,5,7-triazabicyclo [4.4.0] ec-5-ene (TBD) with ratios nTBD/nTMC ranging between 1/20 and 1/400. In all cases, the reaction proceeds very rapidly, even faster than in the presence of alcohol initiators, and provides PTMC with molecular weights up to Mn = 34,000 g mol−1. Characterization of the obtained PTMC samples by MALDI-TOF mass spectrometry, triple detection size exclusion chromatography and 1H NMR spectroscopy reveals the presence of both linear and cyclic polymer chains.

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Taramasso, Lucia, Antonio Falletta, Elena Ricci, Giancarlo Orofino, Nicola Squillace, Barbara Menzaghi, Giuseppe Vittorio De Socio, et al. "Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study." Viruses 14, no. 11 (October 22, 2022): 2315. http://dx.doi.org/10.3390/v14112315.

Повний текст джерела

Анотація:

The aim of the present study was to evaluate CD4/CD8 dynamics in patients on dolutegravir (DTG)-based two-drug regimens (2DRs) and compare them with DTG-containing triple-drug regimens (3DRs). A prospective observational study was performed in the context of the SCOLTA cohort. Experienced PWH with HIV-RNA < 50 copies/mL were included if they were on the DTG-2DR, the DTG + tenofovir/emtricitabine (TDF/FTC) regimen, the DTG + tenofovir alafenamide (TAF)/FTC regimen, or the DTG + abacavir/lamivudine (ABC/3TC) regimen; they were followed-up for at least one year. A total of 533 PWH were enrolled, 120 in the DTG + 3TC group, 38 in the DTG + protease inhibitors (PI) group, 67 in the DTG + rilpivirine (RPV) group, 49 in the DTG + TDF/FTC group, 27 in the DTG + TAF/FTC group, and 232 in the DTG + ABC/3TC group. After one year, the CD4/CD8 ratio significantly increased in the PWH treated with DTG + 3TC (+0.08 ± 0.26), DTG + TDF/FTC (+0.1 ± 0.19), and DTG + ABC/3TC (+0.08 ± 0.25). At two years, the CD4/CD8 increase was confirmed for PWH on DTG + TDF/FTC (+0.16 ± 0.28) and DTG + ABC/3TC (+0.1 ± 0.3). In the SCOLTA cohort, PWH on 2DRs experienced a CD4/CD8 increase only in the DTG + 3TC group. Controlled studies with longer follow-up will clarify the long-term immunological and clinical impacts of DTG-2DR.

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Fukuda, Norimasa, Christian Jayr, Ahmed Lazrak, Yibing Wang, Rudolf Lucas, Sadis Matalon та Michael A. Matthay. "Mechanisms of TNF-α stimulation of amiloride-sensitive sodium transport across alveolar epithelium". American Journal of Physiology-Lung Cellular and Molecular Physiology 280, № 6 (1 червня 2001): L1258—L1265. http://dx.doi.org/10.1152/ajplung.2001.280.6.l1258.

Повний текст джерела

Анотація:

Because tumor necrosis factor (TNF)-α can upregulate alveolar fluid clearance (AFC) in pneumonia or septic peritonitis, the mechanisms responsible for the TNF-α-mediated increase in epithelial fluid transport were studied. In rats, 5 μg of TNF-α in the alveolar instillate increased AFC by 67%. This increase was inhibited by amiloride but not by propranolol. We also tested a triple-mutant TNF-α that is deficient in the lectinlike tip portion of the molecule responsible for its membrane conductance effect; the mutant also has decreased binding affinity to both TNF-α receptors. The triple-mutant TNF-α did not increase AFC. Perfusion of human A549 cells, patched in the whole cell mode, with TNF-α (120 ng/ml) resulted in a sustained increase in Na+currents from 82 ± 9 to 549 ± 146 pA ( P < 0.005; n = 6). The TNF-α-elicited Na+current was inhibited by amiloride, and there was no change when A549 cells were perfused with the triple-mutant TNF-α or after preincubation with blocking antibodies to the two TNF-α receptors before perfusion with TNF-α. In conclusion, although TNF- α can initiate acute inflammation and edema formation in the lung, TNF-α can also increase AFC by an amiloride-sensitive, cAMP-independent mechanism that enhances the resolution of alveolar edema in pathological conditions by either binding to its receptors or activating Na+channels by means of its lectinlike domain.

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Nakazaki, Jotaro, Michio M. Matsushita, Akira Izuoka, and Tadashi Sugawara. "Novel spin-polarized TTF donors affording ground state triplet cation diradicals." Tetrahedron Letters 40, no. 27 (July 1999): 5027–30. http://dx.doi.org/10.1016/s0040-4039(99)00925-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Jinyuan Wu, M. Wang, E. Gottschalk, and Z. Shi. "The application of tiny triplet finder (TTF) in BTeV pixel trigger." IEEE Transactions on Nuclear Science 53, no. 3 (June 2006): 671–76. http://dx.doi.org/10.1109/tns.2006.874144.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Furukawa, Ko, Yasuo Sugishima, Hideki Fujiwara, and Toshikazu Nakamura. "Photoinduced Triplet States of Photoconductive TTF Derivatives Including a Fluorescent Group." Chemistry Letters 40, no. 3 (March 5, 2011): 292–94. http://dx.doi.org/10.1246/cl.2011.292.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Kaufman, Richard M., and William J. Savage. "Staphylococcus aureussepsis from one cocomponent of a “triple” apheresis platelet donation." Transfusion 54, no. 7 (July 2014): 1704. http://dx.doi.org/10.1111/trf.12593.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Elsayed Moussa, Mehdi, Stefan Welsch, Luis Dütsch, Martin Piesch, Stephan Reichl, Michael Seidl та Manfred Scheer. "The Triple-Decker Complex [Cp*Fe(µ,η5:η5-P5)Mo(CO)3] as a Building Block in Coordination Chemistry". Molecules 24, № 2 (17 січня 2019): 325. http://dx.doi.org/10.3390/molecules24020325.

Повний текст джерела

Анотація:

Although the triple-decker complex [Cp*Fe(µ,η5:η5-P5)Mo(CO)3] (2) was first reported 26 years ago, its reactivity has not yet been explored. Herein, we report a new high-yielding synthesis of 2 and the isolation of its new polymorph (2’). In addition, we study its reactivity towards AgI and CuI ions. The reaction of 2 with Ag[BF4] selectively produces the coordination compound [Ag{Cp*Fe(µ,η5:η5-P5)Mo(CO)3}2][BF4] (3). Its reaction with Ag[TEF] and Cu[TEF] ([TEF]− = [Al{OC(CF3)3}4]−) leads to the selective formation of the complexes [Ag{Cp*Fe(µ,η5:η5-P5)Mo(CO)3}2][TEF] (4) and [Cu{Cp*Fe(µ,η5:η5-P5)Mo(CO)3}2][TEF] (5), respectively. The X-ray structures of compounds 3–5 each show an MI ion (MI = AgI, CuI) bridged by two P atoms from two triple-decker complexes (2). Additionally, four short MI···CO distances (two to each triple-decker complex 2) participate in stabilizing the coordination sphere of the MI ion. Evidently, the X-ray structure for compound 3 shows a weak interaction of the AgI ion with one fluorine atom of the counterion [BF4]−. Such an Ag···F interaction does not exist for compound 4. These findings demonstrate the possibility of using triple-decker complex 2 as a ligand in coordination chemistry and opening a new perspective in the field of supramolecular chemistry of transition metal compounds with phosphorus-rich complexes.

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Carrod, Andrew J., Alexei Cravcenco, Chen Ye, and Karl Börjesson. "Modulating TTA efficiency through control of high energy triplet states." Journal of Materials Chemistry C 10, no. 12 (2022): 4923–28. http://dx.doi.org/10.1039/d1tc05292f.

Повний текст джерела

Анотація:

It is shown here that positional isomerism of perylene substitution affects high energy triplet states differently. This in turn influences the quantum efficiency of triplet–triplet annihilation photon upconversion.

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Han, Gwan Hee, Ilseon Hwang, Hanbyoul Cho, Kris Ylaya, Jung-A. Choi, Hyunja Kwon, Joon-Yong Chung, Stephen M. Hewitt, and Jae-Hoon Kim. "Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer." International Journal of Molecular Sciences 22, no. 11 (May 27, 2021): 5714. http://dx.doi.org/10.3390/ijms22115714.

Повний текст джерела

Анотація:

Hormone receptor expression patterns often correlate with infiltration of specific lymphocytes in tumors. Specifically, the presence of specific tumor-infiltrating lymphocytes (TILs) with particular hormone receptor expression is reportedly associated with breast cancer, however, this has not been revealed in epithelial ovarian cancer (EOC). Therefore, we investigated the association between hormone receptor expression and TILs in EOC. Here we found that ERα, AR, and GR expression increased in EOC, while PR was significantly reduced and ERβ expression showed a reduced trend compared to normal epithelium. Cluster analysis indicated poor disease-free survival (DFS) in AR+/GR+/PR+ subgroup (triple dominant group); while the Cox proportional-hazards model highlighted the triple dominant group as an independent prognostic factor for DFS. In addition, significant upregulation of FoxP3+ TILs, PD-1, and PD-L1 was observed in the triple dominant group compared to other groups. NanoString analyses further suggested that tumor necrosis factor (TNF) and/or NF-κB signaling pathways were activated with significant upregulation of RELA, MAP3K5, TNFAIP3, BCL2L1, RIPK1, TRAF2, PARP1, and AKT1 in the triple dominant EOC group. The triple dominant subgroup correlates with poor prognosis in EOC. Moreover, the TNF and/or NF-κB signaling pathways may be responsible for hormone-mediated inhibition of the immune microenvironment.

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Wolf, G., A. Schneider, U. Wenzel, U. Helmchen, and R. A. Stahl. "Regulation of glomerular TGF-beta expression in the contralateral kidney of two-kidney, one-clip hypertensive rats." Journal of the American Society of Nephrology 9, no. 5 (May 1998): 763–72. http://dx.doi.org/10.1681/asn.v95763.

Повний текст джерела

Анотація:

Previous studies have demonstrated that angiotensin II stimulates expression of transforming growth factor-beta (TGF-beta) in cultured renal cells. To investigate whether similar mechanisms are operative in vivo, glomerular TGF-beta mRNA expression was investigated in two-kidney, one-clip (2-K 1-C) hypertensive rats. Glomerular TGF-beta1 transcripts were elevated in the clipped kidney 6 d, but not 3 d, after surgery. Later, during the course of the disease (21 to 35 d), TGF-beta1 mRNA was upregulated in contralateral kidneys compared with sham-operated control kidneys. There was no difference in plasma TGF-beta1 levels between 2-K 1-C rats and controls. Treatment with the AT1 receptor antagonist losartan, as well as with triple therapy (hydralazine, reserpine, and hydrochlorothiazide), started 1 d after clipping, significantly reduced systolic BP in hypertensive rats at day 21 after clipping. Both treatments were equally effective in preventing the increase in glomerular TGF-beta1 mRNA and protein expression in the contralateral kidney at day 21. In a second set of experiments, interventional treatment with losartan or triple therapy, starting 14 d after surgery, was investigated. This treatment for 3 wk significantly reduced the increase in TGF-beta1 expression in the contralateral kidney. At day 35 after clipping, considerable glomerular damage and sclerosis were present, mainly in contralateral kidneys. Interventional treatment with losartan or triple therapy partly prevented this glomerular damage of the contralateral kidney. The data demonstrate that TGF-beta1 expression in the contralateral kidney in 2-K 1-C rats is regulated by the increase in systemic BP rather than by direct effects of angiotensin II.

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Thriveni, Karuvaje, Anisha Raju, Girija Ramaswamy, S. Krishnamurthy, and Rekha V. Kumar. "Tumor necrosis factor: An inflammatory microenvironment marker in primary breast cancer patients." International Journal of Molecular and Immuno Oncology 3, no. 1 (February 11, 2018): 24. http://dx.doi.org/10.18203/issn.2456-3994.intjmolimmunooncol20180470.

Повний текст джерела

Анотація:

Aim: The present study was planned to analyze plasma levels of tumor necrosis factor (TNF) in invasive ductal primary breast cancer (BC) patients in a South Indian population. TNF alpha (TNF α) and TNF beta (TNF β) are produced during inflammation as proinflammatory cytokine markers. The plasma levels of TNF α and TNF β (lymphotoxin α) were correlated with clinicopathological features of BC. Materials and Methods: Blood samples were collected from patients before treatment. We analyzed plasma levels of TNF α, and TNF β in 70 female BC cases and 35 age-matched healthy controls using Millipore magnetic bead kits. Results: Plasma TNF α levels in BC cases were significantly elevated (median 10.1 pg/ml) when compared to the control groups. Plasma values of TNF α and TNF β both were significantly elevated in BC patients with hormone receptor negative cases. Plasma TNF α level was elevated in lymph node metastasis and triple negative BC. Plasma values of TNF α inversely correlated with estrogen receptor and progesterone receptor positivity. Conclusion: The plasma levels of TNF α were more significantly overexpressed than TNF β in BC patients. Further, the patients with aggressive cancer had higher levels of inflammation markers. The present study shows that TNF levels were elevated in hormone receptor negative and triple-negative cases.

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Peng, Jiang, Xinyan Guo, Xinpeng Jiang, Dahui Zhao, and Yuguo Ma. "Developing efficient heavy-atom-free photosensitizers applicable to TTA upconversion in polymer films." Chemical Science 7, no. 2 (2016): 1233–37. http://dx.doi.org/10.1039/c5sc03245h.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Lee, joungjae. "Arche-Pattern theory and Trance theory - centered on original pattern, triple structure and transcendence -." Korean Folklore 68 (November 30, 2018): 95–141. http://dx.doi.org/10.21318/tkf.2018.11.68.95.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Yu, Na, Dhruv Sarwal, Ryan Ash, and Florence M. Aslinia. "Triple therapy with adalimumab, ustekinumab and methotrexate for induction of remission in moderate to severe ileocolonic Crohn’s disease with upper gastrointestinal involvement in a biologic-experienced individual." BMJ Case Reports 14, no. 10 (October 2021): e243500. http://dx.doi.org/10.1136/bcr-2021-243500.

Повний текст джерела

Анотація:

Induction of remission in biologic-experienced individuals with moderate to severe Crohn’s disease (CD) can be a challenge. We hereby present a case of CD with secondary non-response to infliximab. Adding methotrexate and switching to ustekinumab plus methotrexate did not stop the inflammatory process. Therefore, combination therapy with two classes of biologics consisting of ustekinumab and adalimumab plus methotrexate was initiated. He achieved clinical remission in 4 weeks and remained on triple therapy for 6 months which was subsequently tailored to adalimumab/methotrexate combination therapy due to insurance restriction on ustekinumab. He remained in remission for the duration of follow-up, 14 months after initiation of triple therapy and 8 months after switching to methotrexate/adalimumab biologic monotherapy. Triple therapy with anti-TNF, IL-12/23 inhibitor and methotrexate could potentially be an option for induction of remission in biologic-experienced individuals with good initial clinical response to anti-TNF agents.

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Ye, Changqing, Liwei Zhou, Xiaomei Wang, and Zuoqin Liang. "Photon upconversion: from two-photon absorption (TPA) to triplet–triplet annihilation (TTA)." Physical Chemistry Chemical Physics 18, no. 16 (2016): 10818–35. http://dx.doi.org/10.1039/c5cp07296d.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Yang, Zi-Shu, Yingying Ning, Hao-Yan Yin, and Jun-Long Zhang. "Lutetium(iii) porphyrinoids as effective triplet photosensitizers for photon upconversion based on triplet–triplet annihilation (TTA)." Inorganic Chemistry Frontiers 5, no. 9 (2018): 2291–99. http://dx.doi.org/10.1039/c8qi00477c.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Wörner, Karl-Fred, та Walter Siebert. "Synthese neuer µ-1,4-Diboracyclohexadien-Tripeldecker-Komplexe [1] / Synthesis of New μ-1,4-Diboracyclohexadiene Triple-Decker Complexes [1]". Zeitschrift für Naturforschung B 44, № 10 (1 жовтня 1989): 1211–13. http://dx.doi.org/10.1515/znb-1989-1012.

Повний текст джерела

Анотація:

1,2,3,4-Tetramethyl-1,4-diboracyclohex-2-ene (1) reacts in THF solution with two equivalents of potassium metal to yield a red solution of the dianion 12-. Reactions of 1·2 K with allylnickel bromide dimer, cyclooctadiene-rhodium chloride dimer or bis(ethene)rhodium chloride dimer give the triple-deckers 3, 4, and 5, respectively. The constitution of the diamagnetic (30 VE) triple-deckers is derived from NMR and MS data.

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Lewandowska, Aleksandra E., Anna Fel, Marcel Thiel, Paulina Czaplewska, Krzysztof Łukaszuk, Jacek R. Wiśniewski, and Stanisław Ołdziej. "Compatibility of Distinct Label-Free Proteomic Workflows in Absolute Quantification of Proteins Linked to the Oocyte Quality in Human Follicular Fluid." International Journal of Molecular Sciences 22, no. 14 (July 10, 2021): 7415. http://dx.doi.org/10.3390/ijms22147415.

Повний текст джерела

Анотація:

We present two separate label-free quantitative workflows based on different high-resolution mass spectrometers and LC setups, which are termed after the utilized instrument: Quad-Orbitrap (nano-LC) and Triple Quad-TOF (micro-LC) and their directed adaptation toward the analysis of human follicular fluid proteome. We identified about 1000 proteins in each distinct workflow using various sample preparation methods. With assistance of the Total Protein Approach, we were able to obtain absolute protein concentrations for each workflow. In a pilot study of twenty samples linked to diverse oocyte quality status from four donors, 455 and 215 proteins were quantified by the Quad-Orbitrap and Triple Quad-TOF workflows, respectively. The concentration values obtained from both workflows correlated to a significant degree. We found reasonable agreement of both workflows in protein fold changes between tested groups, resulting in unified lists of 20 and 22 proteins linked to oocyte maturity and blastocyst development, respectively. The Quad-Orbitrap workflow was best suited for an in-depth analysis without the need of extensive fractionation, especially of low abundant proteome, whereas the Triple Quad-TOF workflow allowed a more robust approach with a greater potential to increase in effectiveness with the growing number of analyzed samples after the initial effort of building a comprehensive spectral library.

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Cho, Seong-Kun, and Won-Ju Cho. "Highly Sensitive and Transparent Urea-EnFET Based Point-of-Care Diagnostic Test Sensor with a Triple-Gate a-IGZO TFT." Sensors 21, no. 14 (July 12, 2021): 4748. http://dx.doi.org/10.3390/s21144748.

Повний текст джерела

Анотація:

In this study, we propose a highly sensitive transparent urea enzymatic field-effect transistor (EnFET) point-of-care (POC) diagnostic test sensor using a triple-gate amorphous indium gallium zinc oxide (a-IGZO) thin-film pH ion-sensitive field-effect transistor (ISFET). The EnFET sensor consists of a urease-immobilized tin-dioxide (SnO2) sensing membrane extended gate (EG) and an a-IGZO thin film transistor (TFT), which acts as the detector and transducer, respectively. To enhance the urea sensitivity, we designed a triple-gate a-IGZO TFT transducer with a top gate (TG) at the top of the channel, a bottom gate (BG) at the bottom of the channel, and a side gate (SG) on the side of the channel. By using capacitive coupling between these gates, an extremely high urea sensitivity of 3632.1 mV/pUrea was accomplished in the range of pUrea 2 to 3.5; this is 50 times greater than the sensitivities observed in prior works. High urea sensitivity and reliability were even obtained in the low pUrea (0.5 to 2) and high pUrea (3.5 to 5) ranges. The proposed urea-EnFET sensor with a triple-gate a-IGZO TFT is therefore expected to be useful for POC diagnostic tests that require high sensitivity and high reliability.

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Nakazaki, Jotaro, Michio M. Matsushita, Akira Izuoka, and Tadashi Sugawara. "ChemInform Abstract: Novel Spin-Polarized TTF Donors Affording Ground State Triplet Cation Diradicals." ChemInform 30, no. 35 (June 13, 2010): no. http://dx.doi.org/10.1002/chin.199935052.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Quiros-Roldan, Eugenia, Alessandra Calabresi, Giuseppe Lapadula, Valeria Tirelli, Silvia Costarelli, Giuliana Cologni, Serena Zaltron, Massimo Puoti, Giampiero Carosi, and Carlo Torti. "Evidence of Long-Term Suppression of Hepatitis B virus DNA by Tenofovir as Rescue Treatment in Patients Coinfected by HIV." Antiviral Therapy 13, no. 3 (April 2008): 341–48. http://dx.doi.org/10.1177/135965350801300315.

Повний текст джерела

Анотація:

Background The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations. Methods HIV–HBV coinfected patients were selected, provided that LMV was included in the first highly active antiretroviral therapy regimen and TDF was subsequently introduced. Results Forty HIV–HBV patients were included, 25 had undetectable HBV DNA on LMV and 15 were failing on LMV treatment. Three cases of triple 173V+180M+ 204V HBV reverse transcriptase (rt) mutants were identified, as well as several mutations or polymorphisms in the surface antigen gene at positions possibly correlating with vaccine escape. A new mutation (rtI233V) was found in one adefovir-naive patient. In 10 patients, uninterrupted TDF treatment led to a sustained treatment response for a median of 160 (interquartile range 111–189) weeks. Two patients underwent intermittent treatment with TDF and LMV, responding any time TDF was reintroduced. In one patient, TDF without LMV provided treatment response. One patient did not respond to TDF because of low treatment adherence. One patient infected with the triple rt mutant did not respond to entecavir, but TDF was successful as rescue. Conclusions Combination therapy with TDF was effective against HBV mutant viruses resistant to LMV and provided sustained control of HBV replication over long-term follow-up, even after entecavir failure. Moreover, suppression of HBV vaccine escape variants could provide important benefits from a public health perspective.

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Gerner-Mauro, Kamryn N., Haruhiko Akiyama, and Jichao Chen. "Redundant and additive functions of the four Lef/Tcf transcription factors in lung epithelial progenitors." Proceedings of the National Academy of Sciences 117, no. 22 (May 15, 2020): 12182–91. http://dx.doi.org/10.1073/pnas.2002082117.

Повний текст джерела

Анотація:

In multicellular organisms, paralogs from gene duplication survive purifying selection by evolving tissue-specific expression and function. Whether this genetic redundancy is also selected for within a single cell type is unclear for multimember paralogs, as exemplified by the four obligatory Lef/Tcf transcription factors of canonical Wnt signaling, mainly due to the complex genetics involved. Using the developing mouse lung as a model system, we generate two quadruple conditional knockouts, four triple mutants, and various combinations of double mutants, showing that the four Lef/Tcf genes function redundantly in the presence of at least two Lef/Tcf paralogs, but additively upon losing additional paralogs to specify and maintain lung epithelial progenitors. Prelung-specification, pan-epithelial double knockouts have no lung phenotype; triple knockouts have varying phenotypes, including defective branching and tracheoesophageal fistulas; and the quadruple knockout barely forms a lung, resembling theCtnnb1mutant. Postlung-specification deletion of all four Lef/Tcf genes leads to branching defects, down-regulation of progenitor genes, premature alveolar differentiation, and derepression of gastrointestinal genes, again phenocopying the correspondingCtnnb1mutant. Our study supports a monotonic, positive signaling relationship between CTNNB1 and Lef/Tcf in lung epithelial progenitors as opposed to reported repressor functions of Lef/Tcf, and represents a thorough in vivo analysis of cell-type-specific genetic redundancy among the four Lef/Tcf paralogs.

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Ye, Changqing, Liwei Zhou, Xiaomei Wang, and Zuoqin Liang. "Correction: Photon upconversion: from two-photon absorption (TPA) to triplet–triplet annihilation (TTA)." Physical Chemistry Chemical Physics 18, no. 10 (2016): 7537. http://dx.doi.org/10.1039/c6cp90051h.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Jia, Wenjing, Qimao Bi, Sirong Jiang, Jihong Tao, Liying liu, Huilan Yue, and Xiaohui Zhao. "Hypoglycemic activity of Codonopsis pilosula (Franch.) Nannf. in vitro and in vivo and its chemical composition identification by UPLC-Triple-TOF-MS/MS." Food & Function 13, no. 5 (2022): 2456–64. http://dx.doi.org/10.1039/d1fo03761g.

Повний текст джерела

Анотація:

Firstly confirmed the a-glucosidase inhibitory effects of Codonopsis pilosula (Franch.) Nannf. in vivo and in vitro. 29 ingredients in this plant were detected and identified by UPLC-Triple-TOF-MS/MS.

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Patial, Sonika, Deborah J. Stumpo, W. Scott Young, James M. Ward, Gordon P. Flake, and Perry J. Blackshear. "Effects of Combined Tristetraprolin/Tumor Necrosis Factor Receptor Deficiency on the Splenic Transcriptome." Molecular and Cellular Biology 36, no. 9 (March 14, 2016): 1395–411. http://dx.doi.org/10.1128/mcb.01068-15.

Повний текст джерела

Анотація:

Tristetraprolin (TTP) acts by binding to AU-rich elements in certain mRNAs, such as tumor necrosis factor (TNF) mRNA, and increasing their decay rates. TTP knockout mice exhibit a profound inflammatory syndrome that is largely due to increased TNF levels. Although TTP's effects on gene expression have been well studied in cultured cells, little is known about its functions in intact tissues. We performed deep RNA sequencing on spleens from TTP knockout mice that were also deficient in both TNF receptors (“triple knockout” mice) to remove the secondary effects of excess TNF activity. To help identify posttranscriptionally regulated transcripts, we also compared changes in mature mRNA levels to levels of transiently expressed pre-mRNA. In the triple knockout spleens, levels of 3,014 transcripts were significantly affected by 1.5-fold or more, but only a small fraction exhibited differential mRNA/pre-mRNA changes suggestive of increased mRNA stability. Transferrin receptor mRNA, which contains two highly conserved potential TTP binding sites, was significantly upregulated relative to its pre-mRNA. This was reflected in increased transferrin receptor expression and increased splenic iron/hemosiderin deposition. Our results suggest that TTP deficiency has profound effects on the splenic transcriptome, even in the absence of secondary increases in TNF activity.

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Zhang, Jianpeng, Yanyan Zhou, Yuan Yao, Zhenyu Cheng, Ting Gao, Hongfeng Li, and Pengfei Yan. "A light triggered optical and chiroptical switch based on a homochiral Eu2L3 helicate." Journal of Materials Chemistry C 8, no. 20 (2020): 6788–96. http://dx.doi.org/10.1039/d0tc01044h.

Повний текст джерела

Анотація:

A pair of homochiral triple-stranded helicates [Eu₂(o-L^RR)₃](TOf)₆ and [Eu₂(o-L^SS)₃](TOf)₆ show light-responsive optical (UV and PL) and chiroptical (ECD and CPL) switching properties upon alternating UV and visible light irradiation.

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Bloch, Mark, Maria Farris, Dominic Tilden, Andrew Gowers, and Nicola Cunningham. "Triple-class HIV antiretroviral therapy failure in an Australian primary care setting." Sexual Health 7, no. 1 (2010): 17. http://dx.doi.org/10.1071/sh09039.

Повний текст джерела

Анотація:

Objective: To determine the prevalence, characteristics and virological outcomes of triple-class antiretroviral drug failure (TCF) and triple-class virological failure (TCVF) in HIV-infected patients attending an Australian high caseload primary care clinic. Methods: Cross-sectional observational study using a retrospective review of electronic medical records from 1007 patients with HIV attending Holdsworth House Medical Practice in Darlinghurst, Australia, between 2007 and 2008. TCF was defined as failure (virological, immunological, clinical, intolerance or other) of at least one drug in each of the three major classes of highly active antiretroviral therapy. Results: A total of 51 patients (5.1%) with TCF were identified. Of these patients, 31.4% had experienced virological failure of each of the three main drug classes. Eighty-eight percent of patients with TCF and 75% of patients with TCVF had achieved virological suppression (HIV RNA <400 copies mL–1). Total mean (s.d.) duration on antiretroviral therapy (ART) was 12.2 (3.3) years, with patients receiving an average of 18 antiretroviral drugs during this period. Reasons for treatment change included intolerance (88% of patients), virological failure (84%), immunological failure (24%) and poor adherence (20%). Conclusions: The prevalence of TCF and TCVF in patients with long-term HIV infection and extensive antiretroviral experience is low in primary care sites. Despite experiencing failure to the three main classes of ART, successful virological outcomes are still achievable in the majority of such patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Chen, Chunli, Shicheng Wang, and Ping Liu. "Deferoxamine Enhanced Mitochondrial Iron Accumulation and Promoted Cell Migration in Triple-Negative MDA-MB-231 Breast Cancer Cells Via a ROS-Dependent Mechanism." International Journal of Molecular Sciences 20, no. 19 (October 8, 2019): 4952. http://dx.doi.org/10.3390/ijms20194952.

Повний текст джерела

Анотація:

In our previous study, Deferoxamine (DFO) increased the iron concentration by upregulating the expression levels of TfR1 and DMT1 and exacerbated the migration of triple-negative breast cancer cells. However, the mechanisms of iron distribution and utilization in triple-negative breast cancer cells with a DFO-induced iron deficiency are still unclear. In this study, triple-negative MDA-MB-231 and estrogen receptor (ER)-positive MCF-7 breast cancer cells were used to investigate the mechanisms of iron distribution and utilization with a DFO-induced iron deficiency. We found that the mitochondrial iron concentration was elevated in MDA-MB-231 cells, while it was decreased in MCF-7 cells after DFO treatment. The cellular and mitochondrial reactive oxygen species (ROS) levels increased in both breast cancer cell types under DFO-induced iron-deficient conditions. However, the increased ROS levels had different effects on the different breast cancer cell types: Cell viability was inhibited and apoptosis was enhanced in MCF-7 cells, but cell viability was maintained and cell migration was promoted in MDA-MB-231 cells through the ROS/NF-κB and ROS/TGF-β signaling pathways. Collectively, this study suggests that under DFO-induced iron-deficient conditions, the increased mitochondrial iron levels in triple-negative MDA-MB-231 breast cancer cells would generate large amounts of ROS to activate the NF-κB and TGF-β signaling pathways to promote cell migration.

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Yue, Huilan, Luya Wang, Sirong Jiang, Cailang Banma, Wenjing Jia, Yanduo Tao, and Xiaohui Zhao. "Hypoglycemic effects of Rhodiola crenulata (HK. f. et. Thoms) H. Ohba in vitro and in vivo and its ingredient identification by UPLC-triple-TOF/MS." Food & Function 13, no. 3 (2022): 1659–67. http://dx.doi.org/10.1039/d1fo03436g.

Повний текст джерела

Анотація:

The anti-hyperglycaemic effects of Rhodiola crenulata (HK. f. et. Thoms) H. Ohba (RC) was firstly demonstrated in vivo and in vitro, and 40 ingredients in RC were detected and identified by UPLC-Triple-TOF-MS.

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Nöth, Heinrich, and Martina Thomann. "Metal Tetrahydroborates and Tetrahydroborato Metalates, 17 / Bonding in Cadmium Bis(tetrahydroborate), and the Reaction with Lithium Tetrahydroborate." Zeitschrift für Naturforschung B 45, no. 11 (November 1, 1990): 1482–86. http://dx.doi.org/10.1515/znb-1990-1103.

Повний текст джерела

Анотація:

Cadmium bis(tetrahydroborate) has been prepared from dimethyl cadmium and H3B · THF in tetrahydrofuran. Low temperature 113Cd NMR spectra recorded for THF, monoglyme and diglyme solutions show a septet with 1J(113Cd1H) = 273 Hz. This proves that the BH4⁻ groups are bound to the metal centre via triple hydride bridges. Reaction of Cd(BH4)2 with LiBH4 yields LiCd(BH4)3 quantitatively in diglyme solution.

Стилі APA, Harvard, Vancouver, ISO та ін.

Статті в журналах з теми "TTF triple"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями